Gilead Pays Assembly Bio $35M to License Two Herpes Drug Candidates

source:

[1] Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes (https://finance.yahoo.com/news/gilead-science ...)

Gilead Pays Assembly Bio $35M to License Two Herpes Drug Candidates

Related News

BlackSky Stock Gains 80% as Gen-3 Satellite Goes Live

Google's Dual AI Strategy Wins as OpenAI User Growth Stalls

China's $1.076T Trade Surplus Fuels Yuan Appreciation Bets